7th Translational Research Conference: Myelodysplastic Syndromes
April 23-25, 2020 – Mandelieu-La Napoule, France 

Chairs: Pierre Fenaux, Uwe Platzbecker, Mikkael Sekeres

The conference will be held in the Mandelieu Congress Centre in Mandelieu-La Napoule, France. 

Until recently, information on the biology of MDS and options available for its treatment were limited. A lot of data has accumulated in recent years on the pathophysiology of MDS, particularly on the role of somatic mutations (including in very early disease phase), haploinsufficiency for certain genes, and the impact of abnormalities of the microenvironment. Prognostic factors of the disease have also been refined, with the revised IPSS, and new factors like somatic mutations. Treatment approaches are improving, although not at the same speed, and only allogeneic stem cell transplantation remains potentially curative.
The 7th ESH Conference on MDS is designed to provide time and multiple opportunities for critical discussion and informal scientific interaction with internationally recognized experts in the field.

Learning objectives:

  • Learn how to optimally diagnose MDS, mainly by morphological analysis and cytogenetics, but also through the use of new tools, mainly molecular analysis. 

  • Improve ability to analyze prognostic factors, including new ones (revised IPSS, molecular analysis).
  • Review current treatment of MDS, in both the high risk and low risk settings, ranging from single follow up to allogeneic stem cell transplantation.
  • Acquire improved knowledge of emerging treatments, based on targeted therapies and well conducted clinical trials. Diagnostic, prognostic and therapeutic issues will be presented by the faculty and ample time will be devoted to discussion with delegates.

IPSS-R MDS Risk Assessment Calculator

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator

calculator

Click here

MDS Fact Sheet

MDS Factsheet for GPs General Practicioners

MDS Fact Sheet

Click here

Varicella Vaccine in MDS

Urgent Clarification on varicella vaccine policy

Current advice from the UK MDS Forum is not to give the Live Varicella Vaccine to patients with MDS.

Please read below correspondence between Professor Salisbury and Dr George Follows, the latter on behalf of the CLL Forum, on the varicella vaccine policy.
This is an external link to the British Society for Haematology  Click here

NICE Guideline

Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.

NICE logo

Click here

BSH Guidelines

This is an external link to the home of the British Society for Haematology (BSH). 

BSH Logo Strapline RGB

Click here